Evgeny Zaytsev

Evgeny Zaytsev, apart from his active participation in RMI Partners, is also a member of the Board of Directors of Clearside Biomedical, AteaPharmaceuticals, Epic Sciences, NovaDigmTherapeutics, Tragara Pharmaceuticals and Transcend Medical. Evgeny is a successful venture capitalist with more than twelve years’ investment experience in life sciences. Before joining RMI Partners he was a cofounder and general partner at Helix Ventures (Palo Alto, California) – an investment company focused on innovative therapeutic technologies (biopharmaceuticals and medical devices). Before that Evgeny was a partner at Pitch Johnson’s pioneer venture investment company Asset Management Company, one of the oldest venture firms in Silicon Valley. Evgeny has been involved in more than 30 investments in biomedical companies, including such success stories of venture capital as BiPar Sciences (acquired by Sanofi-Aventis), Chimerix (IPO NADSDAQ: CMRX), Enteric Medical Technologies (acquired by Boston Scientific), Fusion Medical Technologies (acquired by Baxter International), MicroVention (acquired by Terumo Corporation) and Coherus Biosciences (NASDAQ: CHRS). In his early career Evgeny was a Chief Scientific Officer at the Institute of Regional Medico-Ecological Problemsin Barnaul, the lead institute of the federal research program called “Semipalatinsk Nuclear Test Site – Altai” that was researching the consequences of nuclear tests for the environmental and human health. During seven yearsof his service, the Institute developed into a globally recognized research center focused on radioactive exposure consequences for human health. Evgeny Zaytsev is an active business community leaderin Russian and Silicon Valley. He was one of the founders the first president of US-Russia Technology Symposium at Stanford University (now Global Technology Symposium), and the annual Silicon Valley Open Doors investment conference. Evgeny Zaytsev is an author of more than 70 scientific and business publications on entrepreneurship, venture capital and biotechnology. Evgeny Zaytsev received his M.D. (cum laude) in 1991 and his Ph.D. in Medicine in 1993, both from the Altai State Medical University. He earned his MBA from the Stanford Graduate School of Business (California) in 2002